DVA Share Price Performance
US$152.54
5.80 (3.95%)
0.5% overvalued intrinsic discount
US$151.71
Fair Value
Price US$152.54
AnalystConsensusTarget US$151.71
AnalystHighTarget US$179.66
AnalystLowTarget US$126.00
Fair ValueUS$151.71
Share Pricen/a
DaVita Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 45 Fair Values set on narratives written by author
DVA Community Narratives
AN
Fair Value US$151.71 0.5% overvalued intrinsic discount
DVA: Policy Shifts And Operational Recovery Will Shape Outlook In 2025
1users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
Fair Value US$179.66 15.1% undervalued intrinsic discount
AI And Integrated Kidney Care Will Drive Stronger Margins And Durable Earnings Power
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$126 21.1% overvalued intrinsic discount
AI And Clinical Platform Spending Will Depress Margins Before Long Term Kidney Care Benefits Emerge
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
DVA: Policy Shifts And Operational Recovery Will Shape Outlook In 2025
Key Takeaways Structural cost reductions and clinical innovation are improving operational efficiency, patient outcomes, and margins, mitigating risk from volume fluctuations. Strategic international expansion is driving diversified growth and presents opportunities for further revenue and margin gains.Read more
284
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
US$151.71
0.5% overvalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
3.71% p.a.
Profit Margin
6.01%
Future PE
11.01x
Price in 2029
US$187.22
AI And Clinical Platform Spending Will Depress Margins Before Long Term Kidney Care Benefits Emerge
Catalysts About DaVita DaVita provides kidney care services, including dialysis and value based care programs for patients with chronic and end stage kidney disease. What are the underlying business or industry changes driving this perspective?Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$126
21.1% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
4.76% p.a.
Profit Margin
5.24%
Future PE
11.28x
Price in 2029
US$159.55
AI And Integrated Kidney Care Will Drive Stronger Margins And Durable Earnings Power
Catalysts About DaVita DaVita provides kidney care services, including dialysis and value based integrated kidney care programs, to patients in the United States and internationally. What are the underlying business or industry changes driving this perspective?Read more
29
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$179.66
15.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
4.82% p.a.
Profit Margin
7.28%
Future PE
11.53x
Price in 2028
US$226.94
Trending Discussion
Recently Updated Narratives
AN
DVA: Buybacks And Richer P/E Assumptions Will Shape Future Return Potential
Fair Value: US$151.71 0.5% overvalued intrinsic discount
18 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AI And Clinical Platform Spending Will Depress Margins Before Long Term Kidney Care Benefits Emerge
Fair Value: US$126 21.1% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AI And Integrated Kidney Care Will Drive Stronger Margins And Durable Earnings Power
Fair Value: US$179.66 15.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
DaVita Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 10.81
- 32.26%
- 5.29%
- 870.8%
About DVA
- Founded
- 1994
- Employees
- 78000
- CEO
- WebsiteView website
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
